Last updated: 2026-09-04 21:28:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Lunai Bioworks Inc. (LNAI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,37, with a market capitalization of $10,88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,21 to $13,28. This page covers its latest market performance, valuation, price trends and company information.
$10,88M | |
$2,31 | |
$13,28 | |
$1,21 | |
$2,35 | |
12,37K | |
-- | |
-- | |
$13,28 | |
$1,21 | |
-- | |
-- |
Lunai Bioworks Inc. (LNAI) is trading at $2,41 in after-hours trading as of 2026-09-04 20:32:00, up 2,55% ($0,06) from the regular-session close of $2,35.
After-hours trading shows how investors are pricing LNAI after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Lunai Bioworks Inc. (LNAI) moved from $2,38 to $2,37, representing a decline of 0,13% ($0,00).
The stock traded between $2,31 and $2,48 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 33,37 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 9,6%
LNAI is currently trading at $2,37, placing it 9,6% of the way from its 52-week low of $1,21 to its 52-week high of $13,28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lunai Bioworks Inc. (LNAI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.